172 related articles for article (PubMed ID: 23638089)
1. Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis.
Azim HA; Singhal S; Ignatiadis M; Desmedt C; Fumagalli D; Veys I; Larsimont D; Piccart M; Michiels S; Sotiriou C
PLoS One; 2013; 8(4):e62451. PubMed ID: 23638089
[TBL] [Abstract][Full Text] [Related]
2. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.
Lindner JL; Loibl S; Denkert C; Ataseven B; Fasching PA; Pfitzner BM; Gerber B; Gade S; Darb-Esfahani S; Sinn BV; Huober J; Engels K; Tesch H; Karn T; Pommerenke F; Liedtke C; Untch M; Müller V; Rack B; Schem C; von Minckwitz G
Ann Oncol; 2015 Jan; 26(1):95-100. PubMed ID: 25355716
[TBL] [Abstract][Full Text] [Related]
3. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.
Ignatiadis M; Singhal SK; Desmedt C; Haibe-Kains B; Criscitiello C; Andre F; Loi S; Piccart M; Michiels S; Sotiriou C
J Clin Oncol; 2012 Jun; 30(16):1996-2004. PubMed ID: 22508827
[TBL] [Abstract][Full Text] [Related]
4. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes.
Watkins G; Douglas-Jones A; Bryce R; Mansel RE; Jiang WG
Prostaglandins Leukot Essent Fatty Acids; 2005 Apr; 72(4):267-72. PubMed ID: 15763438
[TBL] [Abstract][Full Text] [Related]
6. Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer.
Liu R; Lv QL; Yu J; Hu L; Zhang LH; Cheng Y; Zhou HH
Breast Cancer Res Treat; 2015 Jun; 151(3):607-18. PubMed ID: 25981901
[TBL] [Abstract][Full Text] [Related]
7. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
9. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
10. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of secreted protein acidic and rich in cysteine expression in breast cancer tissue and its association with prognosis.
Guo W; Zhang M; Chen Y; Guo S
J Cancer Res Ther; 2017; 13(5):833-836. PubMed ID: 29237913
[TBL] [Abstract][Full Text] [Related]
12. Secreted protein acidic and rich in cysteine (SPARC) is associated with nasopharyngeal carcinoma metastasis and poor prognosis.
Wang HY; Li YY; Shao Q; Hou JH; Wang F; Cai MB; Zeng YX; Shao JY
J Transl Med; 2012 Feb; 10():27. PubMed ID: 22321704
[TBL] [Abstract][Full Text] [Related]
13. EXPRESSION OF SPP1 AND SPARC GENES IN TUMOR TISSUE OF PATIENTS WITH BREAST CANCER.
Chekhun V; Pavlova A; Zadvornyi T; Borikun T; Naleskina L; Mushii O; Bazas V; Lukianova N
Exp Oncol; 2024 May; 46(1):13-21. PubMed ID: 38852057
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
[TBL] [Abstract][Full Text] [Related]
15. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
Orsaria P; Grasso A; Ippolito E; Pantano F; Sammarra M; Altomare C; Cagli B; Costa F; Perrone G; Soponaru G; Caggiati L; Vanni G; Buonomo OC; Altomare V
Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
[TBL] [Abstract][Full Text] [Related]
17. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
[TBL] [Abstract][Full Text] [Related]
18. SPARC accelerates biliary tract cancer progression through CTGF-mediated tumor-stroma interactions: SPARC as a prognostic marker of survival after neoadjuvant therapy.
Takayama H; Kobayashi S; Gotoh K; Sasaki K; Iwagami Y; Yamada D; Tomimaru Y; Akita H; Asaoka T; Noda T; Wada H; Takahashi H; Tanemura M; Doki Y; Eguchi H
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10935-10950. PubMed ID: 37330435
[TBL] [Abstract][Full Text] [Related]
19. In phyllodes tumors of the breast expression of SPARC (osteonectin/BM40) mRNA by in situ hybridization correlates with protein expression by immunohistochemistry and is associated with tumor progression.
Kim NI; Kim GE; Lee JS; Park MH
Virchows Arch; 2017 Jan; 470(1):91-98. PubMed ID: 27909812
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
